Extracts Trial Data - It pulls inclusion and exclusion criteria, trial details, and recruiting site locations from trusted sources like clinicaltrials.gov.

Analyzes Patient Information - The tool gathers both structured data, such as lab results and diagnosis codes, as well as unstructured data from free-text clinical documents within the patient’s medical record.

Matches Patients to Trials - Using this information, it assesses the patient’s potential eligibility for ongoing clinical trials recruiting in nearby locations, making it easier for providers to connect patients with relevant research opportunities.

Predicta Med is transforming the care of autoimmune diseases by offering an EMR-integrated platform that accelerates diagnosis and intervention. The platform includes three core modules:

• PredictaAI: The first AI-driven solution designed for early detection and tailored intervention of autoimmune diseases, enhancing diagnostic accuracy and speed.
• PredictaChart: The tool streamlines clinical decision-making, significantly reducing the time spent on patient chart reviews.
• PredictaMatch: A patient eligibility assessment tool, seamlessly embedded in EMRs, providing healthcare providers with relevant treatment options based on a patient’s disease profile.

Together, these modules enable faster, more accurate care decisions, improving outcomes for patients with autoimmune diseases

Antidote is a digital health company focused on accelerating and improving medical research. By combining proprietary technologies, data, and well-established business models, the company is transforming the way patients and researchers connect, so that breakthroughs happen faster. Antidote was launched as TrialReach in 2010 and rebranded to Antidote in 2016. The company is based in the US and the UK.

Antidote is a digital health company focused on accelerating and improving medical research. By combining proprietary technologies, data, and well-established business models, the company is transforming the way patients and researchers connect, so that breakthroughs happen faster. Antidote was launched as TrialReach in 2010 and rebranded to Antidote in 2016. The company is based in the US and the UK.

AI-Driven Patient Matching: Identify high-potential cohorts earlier in their disease progression.

Heatmap Analytics: Pinpoint where your target populations are most concentrated.

AI-Driven Patient Matching: Identify high-potential cohorts earlier in their disease progression.

Heatmap Analytics: Pinpoint where your target populations are most concentrated.